EUCTR2010-024289-24-NO进行中（未招募）不适用
TREATMENT OF PANCREATIC ADENOCARCINOMA BY COMBINING CONTRAST AGENT AND GEMCITABINE UNDER SONICATION - CEUS treatment
Helse Bergen HF, Haukeland Unversity Hospital0 个研究点目标入组 10 人开始时间: 2011年9月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with inoperable pancreatic cancer (ICD-10 C25.0–3) at the Department of Surgical Gastroenterology of Haukeland University Hospital, who have volunteered to participate, will be included.
- •Patients, who meet all the following inclusion criteria, are eligible for the study entry:
- •Patient must be > 18 years of age, inclusive.
- •Patient has a diagnosis of inoperable pancreatic cancer
- •o(ICD-10 C25.0 Malignant neoplasm: Body of pancreas, C25.2 Malignant neoplasm: Tail of pancreas and C25.3 Malignant neoplasm: Pancreatic duct).
- •Histologically verified, locally advanced (nonresectable Stage II/III) or metastatic (Stage IV) adenocarcinoma of the pancreas. •
- •Must be ambulatory with an ECOG performance status 0-2
- •Female patients of child-bearing potential must have a negative serum pregnancy test and use (and agree to continue to use throughout the study) one of the following forms of contraception from the Screening Visit until completion of the first study follow-up visit: hormonal (oral, implant or injection) begun > 15 days prior to the Screening Visit, barrier (e.g., condom, diaphragm with spermicide), intra-uterine device or vasectomised partner (6 months minimum). If required by the Local Ethics Committee, male patients must also agree to practice throughout the study an approved method of birth control.
- •[Note: To be considered NOT of child-bearing potential, female patients must be postmenopausal (with amenorrhea for at least 2 years prior to study entry) or surgically sterile (with physician or insurance documentation of bilateral tubal ligation at least 6 months prior to study entry, or of a hysterectomy and/or bilateral oophorectomy).]
- •Must have lab values as the following: Hemoglobin > 10, neutrophils (polymorphonuclear leukocytes) > 3.5, PLT > 150 and Bilirubin < 75.
- •Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH/GCP, and national/local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 7
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •Patient participated in an investigational study within 30 days prior to study entry (or, if longer, within five half-lives of the last dose of any investigational drug).
- •Patient has severe chronic obstructive pulmonary disease or severe chronic asthma.
- •Patient has a history of cardiovascular ischemia, acute myocardial infarction or unstable angina within 3 months prior to study entry.
- •Patient has a history of any psychiatric disorder or cognitive impairment that would interfere with participation in the study.
- •Patient has a known history of Hepatitis B, Hepatitis C or HIV infection.
- •Patient requires dialysis or has severely impaired renal function, defined as a serum creatinine > 180 mmol/L at the Screening Visit.
- •Patient has severe impairment of liver function, defined as a serum albumin level = 25 g/L and/or a Protrombin Time INR > 2.3 (or APTT > 6 seconds above the upper limit of normal) at the Screening Visit.
- •Patient is pregnant or is breast-feeding.
- •Patient is allergic to or intolerant of gemcitabine
- •Patient is allergic to or intolerant of SonoVue® BRACCO ultrasound contrast agent
- •Any reason why, in the opinion of the investigator, the patient should not participate.
研究者
相似试验
进行中（未招募）
1 期
Treatment of pancreatic adenocarcinoma with the combinationof carboplatin and velparibEUCTR2014-003785-24-HUzsoki Utcai Kórház
进行中（未招募）
1 期
Treatment of Advanced Cancer of the Gastrointestinal Tract in a clinical study with modified allogeneic stem cells from bone marrowPatients suffering from advanced, recurrent or metastatic gastrointestinal adenocarcinoma.MedDRA version: 18.0Level: HLGTClassification code 10017991Term: Gastrointestinal neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000520-29-DEapceth GmbH & Co. KG
招募中
1 期
Chemotherapy for advanced pancreatic cancer with combined usage of gemcitabine and GSK3beta-inhibiting medicinesadvanced pancreatic cancerJPRN-UMIN0000050951)Multidisciplinary Cancer Center,Kanazawa Medical University Hospital 2)Department of Surgical Oncology, Kanazawa Medical University Hospital6
尚未招募
Unknown
A case of pancreatic ductal adenocarcinoma with enteroblastic, neuroendocrine, and squamous differentiation with p53 overexpression and loss of Rb expressioJPRN-UMIN000054196Kobe University Graduate School of Medicine1
已完成
1 期
Ultrasound-assisted Treatment of Inoperable Pancreatic CancerPancreatic AdenocarcinomaNCT01674556Haukeland University Hospital25